Mar 08th 2013 - Edison Investment Research today published a report on quickview entitled "Peanut Flutter". In summary, the report says:
DBV Technologies develops novel immunotherapeutic patches to desensitise patients to potentially fatal food allergies. Its lead product, Viaskin Peanut, is designed to treat patients allergic to this popular legume. This product is currently undergoing a pivotal Phase IIb trial, with data due in mid-2014. The sponsor-lead Phase II ARACHILD study could read-out this year. DBV has just secured Sanofi as producer of the APIs, lending credibility to its Viaskin platform. ARACHILD data and partnership news are the most likely catalysts that could drive the shares this year.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »